Lung adenocarcinomas that are responsive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors possess EGFR mutations and often increased EGFR CNs (55, 56). This evidence concerns the gene EGFR and lung adenocarcinoma.